PUYOU DE POUVOURVILLE Gérard, THURIN Nicolas, ROUYER Magali, JOVÉ Jérémy, GROSS-GOUPIL Marine, HAASER Thibaud, REBILLARD Xavier, SOULIÉ Michel, CAPONE Camille, BAZIL Marie-Laure, MESSAOUD Fatiha, LAMARQUE Stéphanie, BIGNON Emmanuelle, DROZ-PERROTEAU Cécile, MOORE Nicholas, BLIN Patrick
The aim of the article is to conduct the direct comparison of abiraterone acetate and docetaxel for first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) in real-life settings. The findings underline the interest of oral abiraterone acetate over intravenous docetaxel as the first-line treatment option in mCRPC.
THURIN, N., ROUYER, M., JOVÉ, J., GROSS-GOUPIL, M., HAASER, T., REBILLARD, X. … BLIN, P. (2022). Abiraterone acetate versus docetaxel for metastatic castration-resistant prostate cancer: a cohort study within the French nationwide claims database. Expert Review of Clinical Pharmacology, 15(9), pp. 1139-1145.